Drugs / Aluminum hydroxide suspension
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04915768 | Jan 2023 → Jul 2025 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Aluminum hydroxide suspension | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04915768 ↗ |
| Known as | Alum | “CH505 cTrimer, 300 mcg admixed with (3 mcg) 3M-052-AF + (500 mcg) Aluminum Hydroxide suspension (Alum) administered at months 0, 2, 4, 8 and 12.” NCT04915768 ↗ |